Caris Life Sciences (CAI) vs Concentra Group Parent (CON)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Concentra Group Parent (CON) has outperformed Caris Life Sciences (CAI) over the past year, gaining 73.7% versus a loss of 14.2%. Caris Life Sciences is the larger company by market cap ($7.55 billion vs $4.62 billion), about 1.6 times the size. On valuation, Concentra Group Parent trades at a lower forward P/E (19.7x vs 72.6x for Caris Life Sciences).
Concentra Group Parent pays a dividend yielding 0.69%, while Caris Life Sciences does not currently pay one. Concentra Group Parent converts more of its revenue into profit, with a net margin of 7.7% versus -8.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAI | CON |
|---|---|---|
| Share price | $26.72 | $36.21 |
| Market cap | $7.55B | $4.62B |
| 1-day change | -1.40% | -0.52% |
| YTD return | +0.44% | +84.96% |
| 1-year return | -14.19% | +73.66% |
| P/E ratio (TTM) | 15.81 | 23.36 |
| Forward P/E | 72.57 | 19.67 |
| EPS (TTM) | $1.69 | $1.55 |
| Dividend yield | 0.00% | 0.69% |
| Annual dividend | $0.00 | $0.25 |
| Revenue (latest FY) | $812.03M | $2.16B |
| Revenue growth (YoY) | +96.97% | +13.85% |
| Net income (latest FY) | $-68.09M | $166.41M |
| Gross margin | — | 28.34% |
| Operating margin | 5.56% | 15.44% |
| Net margin | -8.38% | 7.69% |
| 52-week high | $33.65 | $36.83 |
| 52-week low | $14.19 | $18.55 |
| Distance from 52-week high | -20.59% | -1.68% |
| Analyst consensus | buy | none |
| Avg. price target upside | +8.83% | +13.23% |
| Average volume | 4.93M | 918.57K |
| Shares outstanding | 282.68M | 127.52M |
| Employees | 1,846 | 9,967 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CON has outperformed CAI by 87.9 percentage points over the past year.
- Concentra Group Parent trades at a higher earnings multiple (23.4x vs 15.8x trailing P/E).
- Concentra Group Parent is more profitable, keeping 7.7 cents of every revenue dollar as net income versus -8.4 cents for Caris Life Sciences.
- Caris Life Sciences grew revenue faster in its latest fiscal year (+96.97% vs +13.85%).
About Caris Life Sciences
CAI stock →Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.
Health Care · Medical Specialities · 1,846 employees
About Concentra Group Parent
CON stock →Concentra Group Holdings Parent, Inc. provides occupational health services in the United States.
Health Care · Medical Specialities · 9,967 employees
CAI vs CON FAQ
Which is bigger, Caris Life Sciences or Concentra Group Parent?
Caris Life Sciences (CAI) is larger, with a market capitalization of $7.55B compared with $4.62B for Concentra Group Parent (CON).
Which stock has performed better over the past year, CAI or CON?
CON returned +73.66% over the past 12 months, compared with -14.19% for CAI (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CAI or CON?
CAI has the lower trailing P/E at 15.8, versus 23.4 for CON. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Caris Life Sciences or Concentra Group Parent?
Concentra Group Parent pays a dividend yielding 0.69%, while Caris Life Sciences does not currently pay a regular dividend.
Are Caris Life Sciences and Concentra Group Parent in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.